No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki

The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using dat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Toriyama, Eo, Hata, Tomoko, Yokota, Ken‐ichi, Chiwata, Masahiko, Kamijo, Rena, Hashimoto, Miki, Taguchi, Masataka, Horai, Makiko, Matsuo, Masatoshi, Matsuo, Emi, Takasaki, Yumi, Kawaguchi, Yasuhisa, Itonaga, Hidehiro, Sato, Shinya, Ando, Koji, Sawayama, Yasushi, Taguchi, Jun, Imaizumi, Yoshitaka, Tsushima, Hideki, Jo, Tatsuro, Yoshida, Shinichiro, Moriuchi, Yukiyoshi, Miyazaki, Yasushi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7734160/
https://ncbi.nlm.nih.gov/pubmed/32939867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14653
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados